J&J Says Amgen Biosimilar Infringes Patents For $9B Product
Janssen is urging a Delaware federal court to block Amgen from allegedly launching a copycat version of its blockbuster immunosuppressive product Stelara, saying the biosimilar would infringe a pair of patents....To view the full article, register now.
Already a subscriber? Click here to view full article